Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment

Alzheimer’s disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the sympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Siqiang, Zhang, Min, Xu, Dongsheng, Zhang, Yiying, Qiu, Lisha, Tian, Changhai, Zheng, Jialin Charlie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422611/
https://www.ncbi.nlm.nih.gov/pubmed/25949812
http://dx.doi.org/10.1186/s40035-015-0028-y
_version_ 1782370081755365376
author Lai, Siqiang
Zhang, Min
Xu, Dongsheng
Zhang, Yiying
Qiu, Lisha
Tian, Changhai
Zheng, Jialin Charlie
author_facet Lai, Siqiang
Zhang, Min
Xu, Dongsheng
Zhang, Yiying
Qiu, Lisha
Tian, Changhai
Zheng, Jialin Charlie
author_sort Lai, Siqiang
collection PubMed
description Alzheimer’s disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.
format Online
Article
Text
id pubmed-4422611
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44226112015-05-07 Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment Lai, Siqiang Zhang, Min Xu, Dongsheng Zhang, Yiying Qiu, Lisha Tian, Changhai Zheng, Jialin Charlie Transl Neurodegener Review Alzheimer’s disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment. BioMed Central 2015-04-18 /pmc/articles/PMC4422611/ /pubmed/25949812 http://dx.doi.org/10.1186/s40035-015-0028-y Text en © Lai et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Lai, Siqiang
Zhang, Min
Xu, Dongsheng
Zhang, Yiying
Qiu, Lisha
Tian, Changhai
Zheng, Jialin Charlie
Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title_full Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title_fullStr Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title_full_unstemmed Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title_short Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment
title_sort direct reprogramming of induced neural progenitors: a new promising strategy for ad treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422611/
https://www.ncbi.nlm.nih.gov/pubmed/25949812
http://dx.doi.org/10.1186/s40035-015-0028-y
work_keys_str_mv AT laisiqiang directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT zhangmin directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT xudongsheng directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT zhangyiying directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT qiulisha directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT tianchanghai directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment
AT zhengjialincharlie directreprogrammingofinducedneuralprogenitorsanewpromisingstrategyforadtreatment

Ejemplares similares